February 8, 2011

Raloxifene, a selective estrogen receptor modulator, is renoprotective: a post-hoc analysis

.   .   

This study is a post-hoc analysis of the Multiple Outcomes of Raloxifene Evaluation Trial, a double-masked, placebo-controlled randomized clinical trial of post-menopausal women with osteoporosis who were randomized to raloxifene or placebo. Compared with those in the placebo group, participants on raloxifene had a significantly slower yearly rate of decrease in eGFR.

Related Articles:

Bone Mineral Metabolism, Chronic Kidney Disease

Comments are closed.